Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

687 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initial Estimated Glomerular Filtration Rate Decline and Long-Term Renal Function During Intensive Antihypertensive Therapy: A Post Hoc Analysis of the SPRINT and ACCORD-BP Randomized Controlled Trials.
Collard D, Brouwer TF, Olde Engberink RHG, Zwinderman AH, Vogt L, van den Born BH. Collard D, et al. Among authors: vogt l. Hypertension. 2020 May;75(5):1205-1212. doi: 10.1161/HYPERTENSIONAHA.119.14659. Epub 2020 Mar 30. Hypertension. 2020. PMID: 32223381 Free PMC article.
The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
Vogt L, Navis G, Köster J, Manolis AJ, Reid JL, de Zeeuw D; Angiotensin II Receptor Antagonist Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS) Study Group. Vogt L, et al. J Hypertens. 2005 Nov;23(11):2055-61. doi: 10.1097/01.hjh.0000186829.56372.04. J Hypertens. 2005. PMID: 16208149 Clinical Trial.
Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy.
Vogt L, Chiurchiu C, Chadha-Boreham H, Danaietash P, Dingemanse J, Hadjadj S, Krum H, Navis G, Neuhart E, Parvanova AI, Ruggenenti P, Woittiez AJ, Zimlichman R, Remuzzi G, de Zeeuw D; PROLONG (PROteinuria Lowering with urOteNsin receptor antaGonists) Study Group. Vogt L, et al. Hypertension. 2010 May;55(5):1206-9. doi: 10.1161/HYPERTENSIONAHA.109.149559. Epub 2010 Mar 15. Hypertension. 2010. PMID: 20231521 Clinical Trial.
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
Bangalore S, Fayyad R, Hovingh GK, Laskey R, Vogt L, DeMicco DA, Waters DD; Treating to New Targets Steering Committee and Investigators. Bangalore S, et al. Among authors: vogt l. Am J Cardiol. 2014 Jun 15;113(12):2018-20. doi: 10.1016/j.amjcard.2014.03.046. Epub 2014 Apr 3. Am J Cardiol. 2014. PMID: 24793673 Review.
Role of the vascular wall in sodium homeostasis and salt sensitivity.
Olde Engberink RH, Rorije NM, Homan van der Heide JJ, van den Born BJ, Vogt L. Olde Engberink RH, et al. Among authors: vogt l. J Am Soc Nephrol. 2015 Apr;26(4):777-83. doi: 10.1681/ASN.2014050430. Epub 2014 Oct 7. J Am Soc Nephrol. 2015. PMID: 25294232 Free PMC article. Review.
687 results